grow to approximately 80 percent of neurologists by nine months post-launch. High product satisfaction among current prescribers, as well as continued messaging and physician and patient education, will likely contribute to future growth.
LaunchTrends: Aubagio is a four-wave syndicated report series that specifically tracks the introduction of Aubagio into the market, based on data collected at one month, three months, six months and one year post-commercial availability of Aubagio from primary research with neurologists. The second wave was fielded January 11-14, 2013 with 73 U.S. neurologists followed by qualitative interviews with a subset of 15 survey respondents. Along with awareness and sources of familiarity, the reports assess neurologists' trial, adoption and usage, including anticipated future trends, of Aubagio within the MS market. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Genzyme's promotional efforts and benchmarking against other previously launched MS agents.
In addition to the LaunchTrends: Aubagio report series, BioTrends will track the U. S. uptake of Aubagio in the biannual TreatmentTrends®: Multiple Sclerosis (US) report series. This syndicated primary research report series provides a view of the broader MS market landscape, including all currently approved DMAs and DMAs in late-stage clinical development.
*Source: LaunchTrends: Gilenya Wave 2, BioTrends Research Group, published February 11, 2011
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com
'/>"/>
SOURCE BioTrends Research Group Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park2.
How the alphabet of data processing is growing: Research team generates flying qubits3.
New Approach to Growing Waste to Value Industry in United States4.
BioSpace Spotlights the growing Midwest Life Science Community5.
Enterologics Highlights Growing News on Probiotics on the Web6.
Seahorse Bioscience Ranks No. 1600 on the Inc. 5007.
5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%8.
AllCells, LLC Named to Inc. Magazines 500/5000 List of Fastest Growing Companies9.
Breast cancer cells growing in 3D-matrix revert to normal10.
Ramey & Browning Announces New Location and New Hire Firm Is Well Positioned to Address Growing Client Needs In 201311.
Growing Job-Market Niche Inside The Economic Decline: A Wysebridge Review